Andere Sprachen VolitionRx Limited

Aktien

A12B6K

US9286611077

VNRX

Realtime-Estimate Cboe BZX Andere Börsenplätze 21:49:56 02.05.2024			% 5 Tage	% 1. Jan.
0.888 ^USD	+2.54%		-0.38%	+23.68%

26.04.	VolitionRx Limited kündigt Änderungen im Vorstand an	CI
23.04.	VolitionRx Limited führt über Antech den klinischen Einsatz in den USA und Europa ein	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

VolitionRx Limited Announces Board Changes	26.04.
VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech	23.04.
VolitionRx Limited announced that it has received $0.1 million in funding	26.03.
VolitionRx Limited Reports Earnings Results for the Full Year Ended December 31, 2023	25.03.
North American Morning Briefing : Tech in Focus on -2-	25.03.
VolitionRx Limited Agrees Supply Agreement with Fujifilm Vet Systems Co. Ltd	20.03.
VolitionRx Names Andrew Retter as Chief Medical Officer	19.03.
Volitionrx Limited Appoints Andrew Retter as Chief Medical Officer, Effective April 1, 2024	19.03.
VolitionRx Limited announced that it expects to receive $0.1 million in funding	12.03.
Sector Update: Health Care Stocks Gain Late Afternoon	02.01.
Sector Update: Health Care	02.01.
VolitionRX Shares Soar After $13.0 Million Milestone Payments From Heska	02.01.
VolitionRx Limited Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre	05.12.
VolitionRx Limited announced that it has received ?2.5 million in funding	05.12.
VolitionRX: Q3 Earnings Snapshot	15.11.
VolitionRx Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
Volition and VPG Launch Nu.Q Vet Cancer Test in UK and Ireland	07.11.
VolitionRx Limited and Veterinary Pathology Group joins forces to launch the Nu.Q(R) Vet Cancer Test to veterinary practices in the UK and Ireland	06.11.
VolitionRx Limited Presents Breakthrough Liquid Biopsy Blood Test Method for Early-Stage Cancer	23.10.23
Certain Options of VolitionRx Limited are subject to a Lock-Up Agreement Ending on 30-AUG-2023.	30.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen VolitionRx Limited

Aktien

A12B6K

US9286611077

VNRX

Andere Sprachen

Filter